Tumor Treating Fields and New Paradigms in Glioblastoma Standard of Care (original) (raw)

In EF-11, patients had a progressive disease even after initial treatment with radiotherapy and chemotherapy with TMZ, with an average survival of only 6.6 in cases where TTF was used, with no superiority in relation to the control group (6, 0 months), P = 0.27. After a 1-year survival rate of only 20% in both arms of the research, there was a failure to demonstrate that the use of TTF was superior to the chemotherapeutic regimens normally used. Mrugala., et al. summarized the experience of using TTF in 457 patients in 91 institutions in Abstract The primary tenet of neurosurgical oncology is a survival. Glioblastoma (GBM) is the most common and deadliest primary brain tumor. With more than 14,000 new cases of GBM are diagnosed in US each year. Although new treatment paradigms with a significant impact on the outcomes of many other cancer types, treatment of malignant glioma remains a challenge. Patient survival for an average 14 months from diagnosis despite “standard of care” trea...